- Home
- MGRX vs EVAX Comparison
MGRX vs EVAX Comparison
Compare MGRX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- EVAX
- Stock Information
- Founded
- MGRX 2021
- EVAX 2008
- Country
- MGRX United States
- EVAX Denmark
- Employees
- MGRX N/A
- EVAX N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGRX Technology
- EVAX Health Care
- Exchange
- MGRX Nasdaq
- EVAX Nasdaq
- Market Cap
- MGRX 15.6M
- EVAX 17.8M
- IPO Year
- MGRX 2023
- EVAX 2021
- Fundamental
- Price
- MGRX $1.07
- EVAX $5.66
- Analyst Decision
- MGRX
- EVAX Strong Buy
- Analyst Count
- MGRX 0
- EVAX 3
- Target Price
- MGRX N/A
- EVAX $12.33
- AVG Volume (30 Days)
- MGRX 3.9M
- EVAX 137.4K
- Earning Date
- MGRX 11-14-2025
- EVAX 11-06-2025
- Dividend Yield
- MGRX N/A
- EVAX N/A
- EPS Growth
- MGRX N/A
- EVAX N/A
- EPS
- MGRX N/A
- EVAX N/A
- Revenue
- MGRX $466,908.00
- EVAX $7,650,000.00
- Revenue This Year
- MGRX N/A
- EVAX $129.34
- Revenue Next Year
- MGRX N/A
- EVAX N/A
- P/E Ratio
- MGRX N/A
- EVAX N/A
- Revenue Growth
- MGRX N/A
- EVAX 132.17
- 52 Week Low
- MGRX $0.98
- EVAX $1.20
- 52 Week High
- MGRX $6.15
- EVAX $12.15
- Technical
- Relative Strength Index (RSI)
- MGRX 33.36
- EVAX 50.65
- Support Level
- MGRX $1.02
- EVAX $5.01
- Resistance Level
- MGRX $1.16
- EVAX $5.99
- Average True Range (ATR)
- MGRX 0.28
- EVAX 0.49
- MACD
- MGRX -0.04
- EVAX -0.05
- Stochastic Oscillator
- MGRX 6.29
- EVAX 48.78
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.